Unibest
← Back to patent-cliff list

Orelabrutinib

Tier C — Watch / trade

Orelabrutinib

-
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets：BTK

Brand：YINUOKAI, INNOBRUKA

Indications (approved)：Marginal zone B-cell lymphoma, Mantle cell lymphoma, Chronic lymphocytic leukaemia

Regional status

US
Phase III
2026-03-23
EU
Phase III
2026-03-23
China
Approved
2020-12-25
Japan
-

Synthetic routes & intermediates3 routes

Originator routes × 0Optimised (non-patent) × 3Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OptimisedRoute 1Steps 6 · Total yield /
(I)965082-1-a40381-90-6(II)965082-1-a62068-78-4(III)965082-1-a38496-18-3(IV)965082-1-a221006-66-2(V)965082-1-a864772-18-9(VI)965082-1-a1655504-59-8(VII)965082-1-a286961-14-6(VIII)965082-1-a1655504-60-1(IX)965082-1-a,(IX)965082-1-b1655504-61-2(Xa)965082-1-a,(Xa)965082-1-c1655504-62-3(Xb)965082-1-a2484693-10-7(XI)965082-1-a814-68-6API · Orelabrutinib
CodeCAS No.Intermediate
(I)965082-1-a40381-90-62,6-Dichloronicotinonitrile
(II)965082-1-a62068-78-42,6-Dichloronicotinamide
(III)965082-1-a38496-18-32,6-Dichloropyridine-3-carboxylic acid
(IV)965082-1-a221006-66-2(3-Phenoxyphenyl)boronic acid
(V)965082-1-a864772-18-94,4,5,5-Tetramethyl-2-(3-phenoxyphenyl)-1,3,2-dioxaborolane
(VI)965082-1-a1655504-59-86-Chloro-2-(4-phenoxyphenyl)pyridine-3-carboxamide
(VII)965082-1-a286961-14-6N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester
(VIII)965082-1-a1655504-60-1tert-Butyl 5-carbamoyl-6-(4-phenoxyphenyl)-3',6'-dihydro[2,4'-bipyridine]-1'(2'H)-carboxylate
(IX)965082-1-a,(IX)965082-1-b1655504-61-2tert-Butyl 4-[5-carbamoyl-6-(4-phenoxyphenyl)pyridin-2-yl]piperidine-1-carboxylate
(Xa)965082-1-a,(Xa)965082-1-c1655504-62-32-(4-Phenoxyphenyl)-6-(piperidin-4-yl)pyridine-3-carboxamide
(Xb)965082-1-a2484693-10-72-(4-Phenoxyphenyl)-6-(piperidin-4-yl)pyridine-3-carboxamide hydrogen chloride
(XI)965082-1-a814-68-6AvailableAcryloyl chloride
OptimisedRoute 2Steps 3 · Total yield /
(IX)965082-1-a,(IX)965082-1-b1655504-61-2(XII)965082-1-b,(XII)965082-1-c58657-26-4(XIII)965082-1-b,(XIII)965082-1-c2734847-29-9(XIV)965082-1-b—(XV)965082-1-b79099-07-3(XVI)965082-1-b—API · Orelabrutinib
CodeCAS No.Intermediate
(IX)965082-1-a,(IX)965082-1-b1655504-61-2tert-Butyl 4-[5-carbamoyl-6-(4-phenoxyphenyl)pyridin-2-yl]piperidine-1-carboxylate
(XII)965082-1-b,(XII)965082-1-c58657-26-43-Nitropropanal
(XIII)965082-1-b,(XIII)965082-1-c2734847-29-93-Oxo-3-(4-phenoxyphenyl)propanamide
(XIV)965082-1-b-(2Z)-5-Nitro-2-(4-phenoxybenzoyl)pent-2-enamide
(XV)965082-1-b79099-07-3tert-Butyl 4-oxopiperidine-1-carboxylate
(XVI)965082-1-b-tert-Butyl 4-[(3Z)-4-carbamoyl-1-nitro-5-oxo-5-(4-phenoxyphenyl)pent-3-en-1-yl]-4-hydroxypiperidine-1-carboxylate
OptimisedRoute 3Steps 5 · Total yield /
(Xa)965082-1-a,(Xa)965082-1-c1655504-62-3(XII)965082-1-b,(XII)965082-1-c58657-26-4(XIII)965082-1-b,(XIII)965082-1-c2734847-29-9(XIXa)965082-1-c3612-20-2(XIXb)965082-1-c905986-94-9(XVII)965082-1-c107-02-8(XVIIIa)965082-1-c72447-81-5(XVIIIb)965082-1-c107833-73-8(XXa)965082-1-c—(XXb)965082-1-c—(XXc)965082-1-c—(XXIa)965082-1-c—(XXIb)965082-1-c—API · Orelabrutinib
CodeCAS No.Intermediate
(Xa)965082-1-a,(Xa)965082-1-c1655504-62-32-(4-Phenoxyphenyl)-6-(piperidin-4-yl)pyridine-3-carboxamide
(XII)965082-1-b,(XII)965082-1-c58657-26-43-Nitropropanal
(XIII)965082-1-b,(XIII)965082-1-c2734847-29-93-Oxo-3-(4-phenoxyphenyl)propanamide
(XIXa)965082-1-c3612-20-21-Benzylpiperidin-4-one
(XIXb)965082-1-c905986-94-91-[(4-Methoxyphenyl)methyl]piperidin-4-one
(XVII)965082-1-c107-02-8Acrylaldehyde
(XVIIIa)965082-1-c72447-81-51,1-Dimethoxy-3-nitropropane
(XVIIIb)965082-1-c107833-73-81,1-Diethoxy-3-nitropropane
(XXa)965082-1-c-1-Benzyl-4-(3,3-dimethoxy-1-nitropropyl)piperidin-4-ol
(XXb)965082-1-c-1-Benzyl-4-(3,3-diethoxy-1-nitropropyl)piperidin-4-ol
(XXc)965082-1-c-4-(3,3-Diethoxy-1-nitropropyl)-1-[(4-methoxyphenyl)methyl]piperidin-4-ol
(XXIa)965082-1-c-(2Z)-5-(1-Benzyl-4-hydroxypiperidin-4-yl)-5-nitro-2-(4-phenoxybenzoyl)pent-2-enamide
(XXIb)965082-1-c-(2Z)-5-[4-Hydroxy-1-[(4-methoxyphenyl)methyl]piperidin-4-yl]-5-nitro-2-(4-phenoxybenzoyl)pent-2-enamide

Frequently asked questions

What are the approved indications of Orelabrutinib?

Approved indications include: Marginal zone B-cell lymphoma, Mantle cell lymphoma, Chronic lymphocytic leukaemia.

When does the Orelabrutinib patent expire?

No public expiry year is available for Orelabrutinib yet; this page updates once verified.

How many synthesis routes are recorded for Orelabrutinib?

3 synthesis routes are recorded; the shortest is 3 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Orelabrutinib intermediates?

1 intermediate CAS of Orelabrutinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Orelabrutinib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27